Expertise

Expertise

Where high-complexity clinical genomics, immune biology, and laboratory software meet in real-world healthcare. Over the past decade, I’ve led molecular labs, built immunogenetics and cancer genomics programs, and consult with a health-tech start-up focused on laboratory informatics. My expertise spans NGS assay design and validation, immunogenetics and NK-cell biology, infectious disease genomics, and scalable LIMS/quality systems for modern diagnostics.

I lead the development and implementation of high-complexity NGS programs across hematologic, solid tumor, hereditary, and liquid biopsy applications. My work establishes clinically validated, accreditation-ready genomic services across multi-site laboratory ecosystems.

High-Complexity Clinical Genomics Programs

Designing, validating, and operationalizing NGS assays for hematologic malignancies, solid tumors, and hereditary applications — integrated into accredited clinical workflows and reporting pipelines.

  • Myeloid NGS panels (first clinically implemented in Alberta)
  • Solid tumor NGS (e.g., TST170) and targeted panels
  • Comprehensive genomic profiling (e.g., Avenio/Foundational CGP)
  • Variant interpretation frameworks and tumor board–ready reporting
  • End-to-end assay lifecycle: feasibility → validation → maintenance

Laboratory Directorship & Regulatory Alignment

ABB-certified High-Complexity Laboratory Director and Clinical Consultant overseeing clinical validity, regulatory compliance, and operational integrity for complex molecular services.

  • Oversight of high-complexity CLIA-style molecular testing
  • Validation protocols, QMS integration, and competency frameworks
  • Building multidisciplinary tumor boards and consultation pathways
  • Interfacing clinical, pathology, and IT teams across sites and countries

Precision Oncology & Clinical Actionability

Turning NGS data into patient management resources: biomarkers, therapies, trials, and prognostic information across varied reimbursement and access landscapes.

  • Somatic variant triage (Tier classification, AMP/ASCO/CAP frameworks)
  • Liquid biopsy interpretation and longitudinal monitoring
  • HRD/TMB/MSI signatures and immunotherapy markers
  • Practical guidance on adopting CGP in resource-variable settings